Hologic introduces QDR 4000 scanner
Bone densitometry firm Hologic (Hall A, #3447) will be breathing easier at its RSNA booth since the Health Care Financing Administration last month published revised Medicare reimbursement rates that correct misprinted figures released earlier this year.
Bone densitometry firm Hologic (Hall A, #3447) will be breathing easier at its RSNA booth since the Health Care Financing Administration last month published revised Medicare reimbursement rates that correct misprinted figures released earlier this year. The misprinted numbers would have sharply reduced Medicare payments for axial bone densitometry and caused many providers to postpone purchases of axial scanners over the summer (SCAN 11/12/97).
On the new product front, the Waltham, MA, company will debut QDR 4000, the newest member of its QDR family of dual-energy x-ray absorptiometry (DEXA) scanners. QDR 4000 is designed to offer the functionality of a full-featured DEXA scanner in a compact and low-cost package, according to Wade Fox, director of marketing.
Hologic will also feature Sahara, a waterless ultrasound densitometer that is awaiting final FDA clearance.
Burnout in Radiology: Key Risk Factors and Promising Solutions
June 9th 2025Recognizing the daunting combination of increasing imaging volume and workforce shortages, these authors discuss key risk factors contributing to burnout and moral injury in radiology, and potential solutions to help preserve well-being among radiologists.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
